Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in STRASBOURG, Alsace – page 56

990 clinical trials in STRASBOURG, Alsace, France across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
STRASBOURG, Alsace at a glance
990
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

990 trials in STRASBOURG, Alsace

Open in trial search

Myasthenia gravis

Not recruiting

Study on the Safety and Tolerability of DNTH103 for Adults with Generalized Myasthenia Gravis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:DNTH103
  • Sponsor:Dianthus Therapeutics Inc.

Non-small cell lung cancer

Not recruiting

Study Comparing Datopotamab Deruxtecan and Docetaxel for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Daiichi Sankyo Inc.

Squamous cell carcinoma of head and neck

Not recruiting

Study on the Safety and Tolerance of Durvalumab and Radiotherapy for Patients with Untreated Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Squamous cell carcinoma of head and neck

Not recruiting

Study on Adding Nivolumab to Cisplatin and Radiotherapy for High-Risk Patients with Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Obliterative bronchiolitis

Not recruiting

Study on Long-Term Safety and Effectiveness of Liposomal Ciclosporin A for Patients with Bronchiolitis Obliterans Syndrome After Lung Transplantation

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ciclosporin A
  • Sponsor:Zambon S.p.A.

Chronic myeloid leukaemia

Not recruiting

Study of ponatinib and azacitidine combination treatment in patients with accelerated phase or blast crisis chronic myelogenous leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Centre Hospitalier De Versailles

Study Comparing Savolitinib and Osimertinib with Chemotherapy for Advanced Non-Small Cell Lung Cancer in Patients with EGFR Mutation and MET Overexpression

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Embolism venous

Not recruiting

Study Comparing Abelacimab and Apixaban for Preventing Blood Clots in Cancer Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Embolism venous+1

Not recruiting

Study on Abelacimab and Dalteparin for Preventing Blood Clots in Patients with Gastrointestinal or Genitourinary Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Neuroendocrine carcinoma of the skin+9

Not recruiting

Study on Reduced Dose Intensity of Pembrolizumab and Drug Combination for Patients with Advanced or Metastatic Cancer Responding to Standard Immunotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Unicancer

Haemophagocytic lymphohistiocytosis

Not recruiting

Study on Itacitinib for Treating Non-Severe Hemophagocytic Lymphohistiocytosis in Adults

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Itacitinib
  • Sponsor:Assistance Publique Hopitaux De Paris

Systemic scleroderma

Not recruiting

Study on Itacitinib for Adults with Diffuse Systemic Sclerosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Itacitinib
  • Sponsor:Assistance Publique Hopitaux De Paris

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in STRASBOURG, Alsace

What the registry says about research in the country

01 Oncology Research

Advanced studies focusing on head and neck cancers, bladder cancer, and multiple myeloma. Novel therapeutic approaches combining immunotherapy with established treatments are being evaluated for improved patient outcomes.

  • EGFR-targeted therapies for head and neck cancer
  • Non-muscle invasive bladder cancer treatment
  • Multiple myeloma consolidation therapy

Innovative combination therapies are being tested to enhance treatment efficacy while maintaining patient safety.

02 Neurological Disorders

Comprehensive research into multiple sclerosis, essential tremor, and ADHD. Studies are evaluating both new and existing medications for improved symptom management and disease control.

  • Multiple sclerosis treatment strategies
  • Essential tremor therapeutic interventions
  • ADHD neural mechanism studies

Advanced neuroimaging techniques are being utilized to understand treatment effects on brain circuits.

03 Autoimmune Conditions

Investigating new treatments for Crohn's disease, Sjögren's Syndrome, and Myasthenia Gravis. Research focuses on innovative therapeutic approaches including microbiota transplantation and targeted immunotherapies.

  • Fecal microbiota transplantation studies
  • Novel antibody treatments
  • Immunomodulatory therapies

These trials aim to improve disease management and patient quality of life through targeted interventions.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.